$USAQ “AllergiEnd®’’s FDA-cleared diagnostic equipment and products allow primary care providers to diagnose and treat many common chronic allergies in their offices. In particular, the number of people in the U.S. affected by allergic disorders, currently estimated to be 60 million, is expected to grow at a double-digit rate while the number of full-time-equivalent allergists and immunologists is expected to decline. In addition to addressing these secular trends and enhancing patient quality of life, AllergiEnd® treatment solutions are also reimbursable from Medicare and commercial insurance providers, further driving revenue opportunities for physicians in their own practices.